Erratum: Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma (Blood (2016) 127: 9 (1102-1108) DOI: 10.1182/blood-2015-08-662627);Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Blood

Volumn 127, Issue 9, 2016, Pages 1102-1108

  Magarotto, Valeria ^a   Bringhen, Sara ^a   Offidani, Massimo ^b   Benevolo, Giulia ^c   Patriarca, Francesca ^d   Mina, Roberto ^a   Falcone, Antonietta Pia ^e   De Paoli, Lorenzo ^f   Pietrantuono, Giuseppe ^g   Gentili, Silvia ^b   Musolino, Caterina ^h   Giuliani, Nicola ^i,j   Bernardini, Annalisa ^a   Conticello, Concetta ^k   Pulini, Stefano ^l   Ciccone, Giovannino ^m   Maisnar, Vladimír ⁿ   Ruggeri, Marina ^a   Zambello, Renato ^o   Guglielmelli, Tommasina ^p   Ledda, Antonio ^q   Liberati, Anna Marina ^r   Montefusco, Vittorio ^s   Hajek, Roman ^t   Boccadoro, Mario ^a   Palumbo, Antonio ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f Amedeo Avogadro University   (Italy)

^g REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^h UNIVERSITY OF MESSINA   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PARMA   (Italy)

^j UNIVERSITY OF PARMA   (Italy)

^k UNIVERSITY OF CATANIA   (Italy)

^l SPIRITO SANTO HOSPITAL   (Italy)

^m Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica   (Italy)

ⁿ UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^o UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^p SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^q Binaghi Hospital   (Italy)

^r S MARIA HOSPITAL   (Italy)

^s NATIONAL CANCER INSTITUTE   (Italy)

^t UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ACUTE HEART INFARCTION; AGED; ANEMIA; ARTICLE; BRONCHITIS; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GERIATRIC PATIENT; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SECOND CANCER; SEPSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DEMOGRAPHY; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84960375377     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2018-02-832048     Document Type: Erratum

References (22)

1. Howlader N, Noone AM, Krapcho M, et al. eds. SEER cancer statistics review, 1975-2010. Bethesda, MD: National Cancer Institute, based on November 2012 SEER data submission posted to the SEER website, 2013. http://seer.cancer.gov/csr/1975-2010/. Accessed May 10, 2015.
2. San Miguel JF, Schlag R, Khuageva NK, et al; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
3. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259-2266.
4. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomibthalidomide compared with bortezomibmelphalanprednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101-5109.
5. Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomibthalidomide compared with bortezomib-melphalanprednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32(7):634-640.
6. Rajkumar SV, Jacobus S, Callander NS, et al; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
7. Palumbo A, Bringhen S, Caravita T, et al; Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825-831.
8. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112(8):3107-3114.
9. Facon T, Mary JY, Hulin C, et al; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218.
10. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664-3670.
11. Wijermans P, Schaafsma M, Termorshuizen F, et al; Dutch-Belgium Cooperative Group HOVON. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28(19):3160-3166.
12. Waage A, Gimsing P, Fayers P, et al; Nordic Myeloma Study Group. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116(9):1405-1412.
13. Beksac M, Haznedar R, Firatli-Tuglular T, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011;86(1):16-22.
14. Palumbo A, Hajek R, Delforge M, et al; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
15. Benboubker L, Dimopoulos MA, Dispenzieri A, et al; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-917.
16. Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074.
17. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
18. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15(3):333-342.
19. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63-69.
20. Stewart AK, Rajkumar SV, Dimopoulos MA, et al; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152.
21. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801-1809.
22. Lonial S, Dimopoulos M, Palumbo A, et al; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621-631.